Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics' Cervical Cancer Test Receives CE Mark

NEW YORK (GenomeWeb) – Cancer Genetics has received CE marking for its DNA probe-based in vitro diagnostic cervical cancer screening test, the company said today.

The CE mark, which shows a product is in compliance with European Union safety laws, will enable the company to market the FISH-based HPV-associated Cancer Test (FHACT) freely in the European Economic Area, which includes the EU member states and the European Free Trade Association, or 31 nations in all.

The FHACT test uses DNA-FISH probes to identify women who are most at risk for cervical disease by screening for genomic changes related to cancer progression. The test can be used on leftover prep specimens and convention Pap smears.

In addition to identifying women at highest risk for cervical disease, the test also can reduce unnecessary and invasive testing and over-treatment among women who are at a lower risk for disease progression, the Rutherford, NJ-based company said.

"Cervical cancer screening is evolving, but there remains a need for more definitive and genomically informed diagnosis," Cancer Genetics CEO Panna Sharma said in a statement.

Having the CE mark will enable the company to expand its FHACT sales in Europe and allow wider global adoption, said he added.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.